Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 29.79% is 15% below its 5-year average of 35.04%, around the middle of its 5-year range (12.80%–50.94%).
As of the fiscal period ended Tuesday, June 30, 2026. 44.70% above its 12-month average of 20.59%.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 29.79%.
DEBT TO ASSETS RATIO
29.79%
DEBT TO ASSETS RATIO AVG TTM
20.59%
DEBT TO ASSETS RATIO AVG 3Y
28.70%
DEBT TO ASSETS RATIO AVG 5Y
35.04%
DEBT TO ASSETS RATIO AVG 10Y
45.23%
DEBT TO ASSETS RATIO AVG 15Y
39.91%
DEBT TO ASSETS RATIO AVG 20Y
46.18%
CURRENT VS TTM AVG
+44.70%
CURRENT VS 3Y AVG
+3.79%
CURRENT VS 5Y AVG
-14.98%
CURRENT VS 10Y AVG
-34.13%
CURRENT VS 15Y AVG
-25.34%
CURRENT VS 20Y AVG
-35.48%
SECTOR MEDIAN · HEALTHCARE
0.09%
median of 874 covered companies
CURRENT VS SECTOR MEDIAN
+33002.09%
vs the sector median at left
ADMA Biologics, Inc.
Market Cap
$2.36B
Debt to Assets Ratio
29.79%
TTM Avg
20.59%
3Y Avg
28.70%
5Y Avg
35.04%
Market Cap
$2.35B
Debt to Assets Ratio
0.11%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$2.34B
Debt to Assets Ratio
0.20%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$2.38B
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$2.30B
Debt to Assets Ratio
0.25%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$2.43B
Debt to Assets Ratio
0.05%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$2.28B
Debt to Assets Ratio
0.11%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$2.24B
Debt to Assets Ratio
0.13%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| ADMA Biologics, Inc. (ADMA) | $2.36B | 29.79% | 20.59% | 28.70% | 35.04% |
| Disc Medicine, Inc. (IRON)vs › | $2.37B | 0.08% | N/A | N/A | N/A |
| Nurix Therapeutics, Inc. (NRIX)vs › | $2.35B | 0.11% | N/A | N/A | N/A |
| UFP Technologies, Inc. (UFPT)vs › | $2.34B | 0.20% | N/A | N/A | N/A |
| Clover Health Investments, Corp. (CLOV)vs › | $2.38B | 0.00% | N/A | N/A | N/A |
| Liquidia Corporation (LQDA)vs › | $2.30B | 0.25% | N/A | N/A | N/A |
| Recursion Pharmaceuticals, Inc. (RXRX)vs › | $2.43B | 0.05% | N/A | N/A | N/A |
| Harmony Biosciences Holdings, Inc. (HRMY)vs › | $2.28B | 0.11% | N/A | N/A | N/A |
| Alamar Biosciences, Inc. (ALMR)vs › | $2.24B | 0.13% | N/A | N/A | N/A |
| Supernus Pharmaceuticals, Inc. (SUPN)vs › | $2.49B | 0.03% | N/A | N/A | N/A |
Debt/Assets
29.8%
Debt/Equity
0.50
Current Ratio
6.97
Interest Coverage
26.9x
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 29.79% |
| 2026-03-31 | 30.73% |
| 2025-12-31 | 12.80% |
| 2025-09-30 | 14.62% |
| 2025-06-30 | 15.01% |
| 2025-03-31 | 16.06% |
| 2024-12-31 | 16.80% |
| 2024-09-30 | 28.51% |
| 2024-06-30 | 37.57% |
| 2024-03-31 | 40.31% |
| 2023-12-31 | 42.96% |
| 2023-09-30 | 43.83% |
| 2023-06-30 | 44.17% |
| 2023-03-31 | 45.70% |
| 2022-12-31 | 44.32% |
| 2022-09-30 | 50.81% |
| 2022-06-30 | 50.94% |
| 2022-03-31 | 47.51% |
| 2021-12-31 | 37.26% |
| 2021-09-30 | 42.65% |
| 2021-06-30 | 43.53% |
| 2021-03-31 | 42.50% |
| 2020-12-31 | 47.03% |
| 2020-09-30 | 52.73% |
| 2020-06-30 | 52.06% |
| 2020-03-31 | 46.62% |
| 2019-12-31 | 66.67% |
| 2019-09-30 | 61.20% |
| 2019-06-30 | 58.63% |
| 2019-03-31 | 73.53% |
| 2018-12-31 | 49.76% |
| 2018-09-30 | 41.31% |
| 2018-06-30 | 37.08% |
| 2018-03-31 | 47.43% |
| 2017-12-31 | 39.78% |
| 2017-09-30 | 42.79% |
| 2017-06-30 | 38.57% |
| 2017-03-31 | 109.88% |
| 2016-12-31 | 85.53% |
| 2016-09-30 | 72.99% |
| 2016-06-30 | 62.64% |
| 2016-03-31 | 80.57% |
| 2015-12-31 | 66.33% |
| 2015-09-30 | 56.08% |
| 2015-06-30 | 51.96% |
| 2015-03-31 | 44.47% |
| 2014-12-31 | 54.98% |
| 2014-09-30 | 39.79% |
| 2014-06-30 | 35.54% |
| 2014-03-31 | 30.93% |
| 2013-12-31 | 15.87% |
| 2013-09-30 | 58.08% |
| 2013-06-30 | 47.08% |
| 2013-03-31 | 36.28% |
| 2012-12-31 | 25.52% |
| 2012-09-30 | 0.69% |
| 2012-06-30 | 0.59% |
| 2012-03-31 | 0.57% |
| 2011-12-31 | 0.00% |
| 2011-09-30 | 0.00% |
| 2011-06-30 | 115343.05% |
| 2011-03-31 | 35931.32% |
| 2010-12-31 | 155419.35% |
| 2010-09-30 | 237.86% |
| 2010-06-30 | 102880.45% |
| 2010-03-31 | 228.63% |
| 2009-12-31 | 84.86% |
| 2009-09-30 | 106.88% |
| 2009-06-30 | 132.46% |
| 2009-03-31 | 67.85% |
| 2008-12-31 | 92.90% |
| 2008-06-30 | 602.87% |
| 2008-03-31 | 168.34% |
| 2007-12-31 | 95.70% |
| 2007-09-30 | 109.01% |
| 2007-06-30 | 68.74% |
| 2007-03-31 | 21.44% |
| 2006-12-31 | 42.80% |
| 2006-09-30 | 32.13% |
